Holen Sie sich die Stockscreener-App
13.54
1.12%
0.15
Handel nachbörslich:
13.54
Schlusskurs vom Vortag:
$13.39
Offen:
$13.4
24-Stunden-Volumen:
353.96K
Relative Volume:
0.38
Marktkapitalisierung:
$1.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.88M
KGV:
-8.7536
EPS:
-1.5468
Netto-Cashflow:
$-104.72M
1W Leistung:
+1.20%
1M Leistung:
-5.31%
6M Leistung:
-50.11%
1J Leistung:
-38.34%
1-Tages-Spanne:
$13.35
$13.67
1-Wochen-Bereich:
$13.31
$14.08
52-Wochen-Spanne:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
13.54 | 1.41B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
What drives Edgewise Therapeutics Inc. stock priceDynamic growth stocks - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Edgewise Therapeutics, Inc. (EWTX) And Encourages Investors to Reach Out - ACCESS Newswire
Readystate Asset Management LP Boosts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - MarketScreener
Is Edgewise Therapeutics Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
Jennison Associates LLC Purchases New Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Inc. Stock Analysis and ForecastRemarkably fast returns - jammulinksnews.com
What analysts say about Edgewise Therapeutics Inc. stockHigh-velocity capital appreciation - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Edgewise Therapeutics, Inc. (EWTX) And Encourages Stockholders to Reach Out - ACCESS Newswire
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
When is the best time to buy Edgewise Therapeutics Inc. stockSmart Growth Low Risk Picks - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - cnhinews.com
why edgewise therapeutics inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplyQuick Profit Idea Stream - Newser
How Edgewise Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Why Edgewise Therapeutics Inc. stock attracts strong analyst attentionSmart Money Signals - Newser
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 7.9%Time to Buy? - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment - MSN
(EWTX) Trading Report - news.stocktradersdaily.com
User - FinancialContent
Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by HC Wainwright - Defense World
HC Wainwright Initiates Edgewise Therapeutics With Buy Rating, $42 Price Target - MarketScreener
Edgewise Therapeutics (EWTX) Initiated with Buy Rating by HC Wainwright | EWTX Stock News - GuruFocus
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder Drug - MSN
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies - WV News
Edgewise Therapeutics stock falls after FDA deems data insufficient for accelerated approval - Investing.com UK
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.8%Here's What Happened - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stake Boosted by GAMMA Investing LLC - MarketBeat
Rhumbline Advisers Purchases 6,440 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $39.78 Average PT from Analysts - MarketBeat
Enliven to sell $200M in stock after positive drug trial - BizWest
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Transcript : Edgewise Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03 - MarketScreener
Bank of America Corp DE Has $1.31 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):